Genzyme drops Sepracoat in US after FDA vote:
This article was originally published in Clinica
Genzyme is to discontinue the development of Sepracoat, its coating solution, in the US, resulting in write-off of around $5 million. In May 1997 the FDA voted against granting approval for the product, which is designed to reduce adhesion formation resulting from indirect trauma during surgery. The product has been CE-marked since 1996. The US company maintains the action will have no impact on the manufacture and sales of related product, Seprafilm, its surgical adhesion preventative, which received FDA approval in mid-1996.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.